Search Results for: dr. oz

Putting the IP in iPS cells: patent war looming?

war

Will intellectual property (IP) wars over patent rights to one of the most exciting new stem cell technologies hold back getting novel therapies to patients such as IPS cells? Unfortunately, it’s very possible. Induced pluripotent stem (iPS) cells are very cool stem cells made from non-stem cells through a process called cellular reprogramming. iPS  cells

Putting the IP in iPS cells: patent war looming? Read More »

WSCS2012: outstanding panel discussion on legal challenges to stem cell research

It was near to a stem cell wonk’s heaven to be in the audience for a panel discussion, entitled Understanding the Legal and Policy Challenges to Stem Cell Research, here at the World Stem Cell summit in Florida late this afternoon. The stellar panel included Jeanne Loring of Scripps, Beth Roxland of Hofstra University and formerly of

WSCS2012: outstanding panel discussion on legal challenges to stem cell research Read More »

A tribute to Nobel Laureate E. Donnall Thomas, a true stem cell pioneer

I was fortunate enough to do my postdoctoral studies at the Fred Hutchinson Cancer Research Center (aka “The Hutch”) in Seattle. I was a postdoc for more years than I’d like to admit, but it was a wonderful experience. The Hutch is the kind of place where you can imagine making the impossible become possible

A tribute to Nobel Laureate E. Donnall Thomas, a true stem cell pioneer Read More »

Moriguchi talks about himself & Yamanaka in new article that now invokes MIT along with Harvard in supposed iPS cell transplants in humans

Did Dr. Hisashi Moriguchi really transplant iPS cells into human patients? The story has the stem cell field abuzz. My mind keeps changing on this one as earlier today I thought the whole thing maybe was a bunch of fluff, but now there is yet another new article (see headline below) in the Daily Yomiuri providing

Moriguchi talks about himself & Yamanaka in new article that now invokes MIT along with Harvard in supposed iPS cell transplants in humans Read More »

Testimony in supermodel stem cell fraud case: “I lied to patients”

“I lied to patients,” testified a weeping, young woman in court related to a fraud allegation involving stem cells. She had worked as an office assistant at a company that injected bogus and potentially dangerous cow-based “stem cell” treatments into human patients. This company, which in different incarnations went by various names including Biomark in

Testimony in supermodel stem cell fraud case: “I lied to patients” Read More »

Transformative idea for peer review: reviewing & grading the reviewers

Do you feel frustrated with the current peer review system in science? I have an idea that might help and it involves the revolutionary idea of reviewer accountability. In other words, authors and grant writers in essence review their reviewers. I’ve made this all the easier for you with templates that you can simply and

Transformative idea for peer review: reviewing & grading the reviewers Read More »

ICMS President Rodriguez interview on adult stem cell regulatory issues

The International Cellular Medicine Society (ICMS) has emerged as an important organization related to stem cell regulatory issues. I think that many people do not understand what ICMS is all about and it certainly evokes strong opinions in the stem cell field. If you care about stem cells then you need to know about ICMS

ICMS President Rodriguez interview on adult stem cell regulatory issues Read More »

Billionaire Malone infuses Regenerative Sciences with millions in cash: what’s the scoop?

john-malone-regenerative

Regenerative Sciences, Inc. just announced in a press release (PR) that John C. Malone (pictured above in their PR), Ph.D. has “joined the Regenexx Team”. Malone has infused the restive stem cell company with millions in cash. Regenerative Sciences is the adult stem cell company run by Dr. Chris Centeno of the Centeno/Schultz Clinic that is locked in

Billionaire Malone infuses Regenerative Sciences with millions in cash: what’s the scoop? Read More »